Safeguard Scientifics has a unique and consistent approach to putting capital to work in the life sciences sector. We target capital efficient diagnostic companies that we believe will have success with applications they submit to the FDA. In addition,...

PixelOptics’ emPower! eyewear is the world’s first and only electronic focusing eyeglasses—focusing faster than the blink of an eye. The technology is embedded inside the lenses and powered by tiny microelectronics hidden inside the frames, providing...

Ninety percent of migraine sufferers experience nausea, while 60 percent experience vomiting because of their migraine. As a result, today’s most common migraine treatments that are administered orally are less effective. Enter Zelrix, or NP101, which...

In America, there are more than 171 million dogs and cats in over 71 million households. Ninety-six percent of the drugs approved for these pets are not generic, whereas 78 percent of prescriptions filled for humans are. New partner company Putney has...

The IPO Task Force unveiled a new effort to ease the IPO road for emerging companies in its report, “Rebuilding the IPO On-Ramp.” The report calls for an easing of regulations that it says are holding back emerging U.S. companies. Among its recommendations,...

Earlier this week we held our Fifth Annual Investor Day 2011 where investors and analysts heard presentations from Safeguard executives and  highlighted partner companies on growth opportunities and value creation strategies. President and CEO Peter...